2.Association of serum vitamin D levels, IL-17a Levels with disease severity among 3- to 18-year-old children with asthma in the Philippine General Hospital.
Kristine TANEGA-ALILING ; Alexander O. TUAZON
Acta Medica Philippina 2022;56(9):89-97
Background. Previous studies show that Vitamin D has an inverse relationship with asthma severity, symptoms, exacerbations, medication usage, and a direct relationship with lung function. IL-17A was found to be increased in asthmatics, which was inhibited by Vitamin D. Associations found between vitamin D, IL-17A, and asthma may support the future role of vitamin D in the treatment of asthma in children.
Objective. To compare vitamin D and IL-17A levels between children with and without asthma and determine their association with asthma severity
Study Design. Cross-sectional study
Methods. There were 44 participants, aged 3 to 18 years: 22 with asthma (12 non-severe, 10 severe) and 22 without asthma. Participants with any disease-altering vitamin D metabolism, intake of vitamin D supplementation, and recent infection were excluded. Serum vitamin D and IL-17A levels were measured in all participants.
Results. There was no significant difference in mean vitamin D levels between participants with asthma (29.6 ± 12.6 ng/mL) and without asthma (27.6 ± 9.5 ng/mL) (p = 0.55) as well as between participants with non-severe asthma (29.8 ± 14.0 ng/mL) and severe asthma (29.4 ± 11.5 ng/mL) (p = 0.95). The overall prevalence of hypovitaminosis D (< 30ng/mL) is 61.4%; 59.1% among those with asthma and 63.6% without asthma. The prevalence of vitamin D insufficiency and/or deficiency did not significantly differ between those with and without asthma (all p-value > 0.05); prevalence ratios were: 1.05 for vitamin D insufficiency, 0.58 for vitamin deficiency, and 0.92 for vitamin D insufficiency and deficiency combined. There was also no significant difference in the prevalence of vitamin D insufficiency and/or deficiency between severe and non-severe asthma (all p-values > 0.05), with prevalence ratios: 0.74 for vitamin D insufficiency, 0.50 for vitamin D deficiency, and 0.75 for vitamin D insufficiency and deficiency combined. Serum IL-17A levels were below the minimum detectable levels in 96% of the participants using the MILLIPLEX Map Human TH17 Magnetic Band Panel; hence, could not be analyzed.
Conclusion. The mean serum vitamin D levels do not differ between children with asthma and healthy controls. There was no significant relationship between mean vitamin D levels and asthma severity. There was no association between the prevalence of vitamin D insufficiency and/or deficiency and asthma and its severity. The overall prevalence of hypovitaminosis D in this study is 61.4%. Serum IL-17A levels were undetectable in 96% of the study population.
Asthma ; Vitamin D ; Interleukin-17
3.Study on dynamic change of serum interleukin-17 and interleukin-10 levels in patients with acute cerebral infar.
Chao-Gui ZHANG ; Chang-Hua QU ; Hua YANG ; Wan-Hong LIU
Chinese Journal of Applied Physiology 2014;30(1):36-37
Cerebral Infarction
;
blood
;
Humans
;
Interleukin-10
;
blood
;
Interleukin-17
;
blood
5.CP-690550 Treatment Ameliorates Established Disease and Provides Long-Term Therapeutic Effects in an SKG Arthritis Model.
Keunhee OH ; Myung Won SEO ; In Gyu KIM ; Young Il HWANG ; Hee Yoon LEE ; Dong Sup LEE
Immune Network 2013;13(6):257-263
Although pathogenesis of human rheumatoid arthritis (RA) remains unclear, arthritogenic T cells and downstream signaling mediators have been shown to play critical roles. An increasing numbers of therapeutic options have been added for the effective control of RA. Nevertheless, there is still a category of patients that fails treatment and suffers from progressive disease. The recently developed immunosuppressant CP-690550, a small molecule JAK kinase inhibitor, has been implicated as an important candidate treatment modality for autoimmune arthritis. In this study, we evaluated the therapeutic effect of CP-690550 on established arthritis using an SKG arthritis model, a pathophysiologically relevant animal model for human RA. CP-690550 treatment revealed remarkable long-term suppressive effects on SKG arthritis when administered to the well-advanced disease (clinical score 3.5~4.0). The treatment effect lasted at least 3 more weeks after cessation of drug infusion, and suppression of disease was correlated with the reduced pro-inflammatory cytokines, including IL-17, IFN-gamma, and IL-6 and increased level of immunoregulatory IL-10.
Arthritis*
;
Arthritis, Rheumatoid
;
Cytokines
;
Humans
;
Interleukin-10
;
Interleukin-17
;
Interleukin-6
;
Models, Animal
;
Phosphotransferases
;
T-Lymphocytes
6.Resistance to Chemotherapy on Tumor Through Cathepsin B-dependent Activation of the NLRP3 Inflammasome.
Eun Jeong KWON ; Young Sang KOH
Journal of Bacteriology and Virology 2013;43(3):233-234
Anticancer drugs kill tumor cells and increase host anti-tumor immunity. Interestingly, gemcitabin (Gem) and 5-fluorouracil (5-FU), widely used anticancer drugs, lead to IL-1beta secretion releasing cathepsin B which activates Nlrp3 inflammasome in myeloid derived suppressor cells (MDSCs). MDSC derived IL-1beta enhance secretion of IL-17 by CD4+ T cells. This mechanism limits the antitumor efficacy of the drugs and promotes tumor growth.
Cathepsin B
;
Cathepsins
;
Fluorouracil
;
Interleukin-17
;
T-Lymphocytes
7.The role of Th17 cells in liver diseases.
Ye ZHANG ; Chang-xing HUANG ; Jiu-ping WANG ; Jian-qi LIAN ; Xue-fan BAI
Chinese Journal of Hepatology 2012;20(4):316-318
9.A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
Sang Jin LEE ; Han Ki PARK ; Yong Sun KIM
Journal of Rheumatic Diseases 2019;26(4):278-281
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
Ear
;
Hearing Loss
;
Humans
;
Interleukin-17
;
Neurosyphilis
;
Spondylitis, Ankylosing
10.Regulation of Osteoclast Differentiation by Cytokine Networks
Dulshara Sachini AMARASEKARA ; Hyeongseok YUN ; Sumi KIM ; Nari LEE ; Hyunjong KIM ; Jaerang RHO
Immune Network 2018;18(1):e8-
Cytokines play a pivotal role in maintaining bone homeostasis. Osteoclasts (OCs), the sole bone resorbing cells, are regulated by numerous cytokines. Macrophage colony-stimulating factor and receptor activator of NF-κB ligand play a central role in OC differentiation, which is also termed osteoclastogenesis. Osteoclastogenic cytokines, including tumor necrosis factor-α, IL-1, IL-6, IL-7, IL-8, IL-11, IL-15, IL-17, IL-23, and IL-34, promote OC differentiation, whereas anti-osteoclastogenic cytokines, including interferon (IFN)-α, IFN-β, IFN-γ, IL-3, IL-4, IL-10, IL-12, IL-27, and IL-33, downregulate OC differentiation. Therefore, dynamic regulation of osteoclastogenic and anti-osteoclastogenic cytokines is important in maintaining the balance between bone-resorbing OCs and bone-forming osteoblasts (OBs), which eventually affects bone integrity. This review outlines the osteoclastogenic and anti-osteoclastogenic properties of cytokines with regard to osteoimmunology, and summarizes our current understanding of the roles these cytokines play in osteoclastogenesis.
Cytokines
;
Homeostasis
;
Interferons
;
Interleukin-1
;
Interleukin-10
;
Interleukin-11
;
Interleukin-12
;
Interleukin-15
;
Interleukin-17
;
Interleukin-23
;
Interleukin-27
;
Interleukin-3
;
Interleukin-33
;
Interleukin-4
;
Interleukin-6
;
Interleukin-7
;
Interleukin-8
;
Macrophage Colony-Stimulating Factor
;
Necrosis
;
Osteoblasts
;
Osteoclasts
;
RANK Ligand